Literature DB >> 17692977

Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial.

Lucyna Pietrzak1, Krzysztof Bujko, Marek P Nowacki, Lucyna Kepka, Janusz Oledzki, Andrzej Rutkowski, Jacek Szmeja, Jozef Kladny, Dariusz Dymecki, Andrzej Wieczorek, Mariusz Pawlak, Tadeusz Lesniak, Teresa Kowalska, Piotr Richter.   

Abstract

BACKGROUND AND
PURPOSE: Patients (N=316) with resectable cT3-4 low-lying and mid-rectal cancer were randomised to receive either preoperative 5x5Gy irradiation with subsequent surgery performed within 7 days or chemoradiation (50.4, 1.8Gy per fraction plus boluses of 5-fluorouracil and leucovorin) followed by surgery after 4-6 weeks. No differences were found in sphincter preservation, survival, local control and late complications. Early complications were less frequent in the short-course group. The aim of this report is to find out whether large doses per fraction of short-course schedule result in more severe anorectal and sexual dysfunction and quality of life (QoL) impairment. MATERIALS AND
METHOD: Patients who were free of disease were asked to answer the QLQ-C30 and those without stoma were, additionally, asked to fill in a questionnaire of anorectal (19 items) and sexual function (1 item).
RESULTS: Two hundred and twenty-two patients (86% response rate) completed the QLQ-C30 and 118 (86% response rate) the anorectal-sexual function questionnaire. The median time from surgery to filling in the QLQ-C30 questionnaire was 12 months, and to filling in the anorectal-sexual function questionnaire - 13 months. We did not find significant differences between the randomised groups regarding QoL and the anorectal and sexual functions. Approximately two-thirds of patients had anorectal function impairment. Approximately 20% of patients stated that this considerably influenced their QoL.
CONCLUSIONS: QoL and the anorectal and sexual functioning did not differ in patients receiving short-course radiotherapy, as compared to those receiving chemoradiation.

Entities:  

Mesh:

Year:  2007        PMID: 17692977     DOI: 10.1016/j.radonc.2007.07.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  34 in total

1.  Modified neoadjuvant short-course radiation therapy in uT3 rectal carcinoma: low local recurrence rate with unchanged overall survival and frequent morbidity.

Authors:  Rainer Kube; Henry Ptok; David Jacob; Jörg Fahlke; Pawel Mroczkowski; Hans Lippert; Gunther Ziegenhardt; Uwe Schmidt; Ingo Gastinger
Journal:  Int J Colorectal Dis       Date:  2009-10-31       Impact factor: 2.571

2.  Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report.

Authors:  Meijin Huang; Jinxin Lin; Xihu Yu; Shen Chen; Liang Kang; Yanhong Deng; Jian Zheng; Yanxin Luo; Lei Wang; Ping Lan; Jianping Wang
Journal:  Int J Colorectal Dis       Date:  2016-06-06       Impact factor: 2.571

Review 3.  Neoadjuvant vs adjuvant pelvic radiotherapy for locally advanced rectal cancer: Which is superior?

Authors:  Sarah Popek; Vassiliki Liana Tsikitis
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

Review 4.  Therapeutic approaches in the management of locally advanced rectal cancer.

Authors:  Simon D Fung-Kee-Fung
Journal:  J Gastrointest Oncol       Date:  2014-10

Review 5.  Sexual dysfunction following rectal cancer surgery.

Authors:  V Celentano; R Cohen; J Warusavitarne; O Faiz; M Chand
Journal:  Int J Colorectal Dis       Date:  2017-05-11       Impact factor: 2.571

Review 6.  The current landscape of locally advanced rectal cancer.

Authors:  Mebea Aklilu; Cathy Eng
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

7.  Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer.

Authors:  Philippe Bulens; Alice Couwenberg; Karin Haustermans; Annelies Debucquoy; Vincent Vandecaveye; Marielle Philippens; Mu Zhou; Olivier Gevaert; Martijn Intven
Journal:  Radiother Oncol       Date:  2018-01-31       Impact factor: 6.280

8.  Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy--long-term results.

Authors:  Matthias Guckenberger; Joern Wulf; Andreas Thalheimer; Daniel Wehner; Arnulf Thiede; Gottfried Müller; Marco Sailer; Michael Flentje
Journal:  Radiat Oncol       Date:  2009-12-21       Impact factor: 3.481

9.  Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery.

Authors:  Salvatore Pucciarelli; Paola Del Bianco; Fabio Efficace; Paola Toppan; Samantha Serpentini; Maria Luisa Friso; Sara Lonardi; Gian Luca De Salvo; Donato Nitti
Journal:  Support Care Cancer       Date:  2009-07-23       Impact factor: 3.603

Review 10.  Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer--a review focusing on open questions.

Authors:  Lutz Moser; Jörg-Peter Ritz; Wolfgang Hinkelbein; Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2007-12-07       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.